Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Rechsteiner

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Diagnostic Pathology|February 13, 2019
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern SwitzerlandAlexandra Grosse, Claudia Grosse, Markus Rechsteiner, et al.
Plos One|August 7, 2019
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcomeClaudia Grosse, Alex Soltermann, Markus Rechsteiner, et al.
Histopathology|September 24, 2023
Pleomorphic adenoma with PLAG1 fusion as an isolated kidney mass: lessons learned from a challenging caseJoão Lobo, Markus Rechsteiner, Niels J Rupp, et al.
Frontiers in Medicine|May 16, 2022
Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney TransplantsOnur Sazpinar, Ariana Gaspert, Daniel Sidler, et al.
American Journal of Clinical Pathology|May 9, 2019
Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E MutationAnne-Laure Leblond, Markus Rechsteiner, Amy Jones, et al.
Oncotarget|January 5, 2017
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinomaCaroline Fanja Razafinjatovo, Daniel Stiehl, Eva Deininger, et al.
Histopathology|April 11, 2022
Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative studyJoão Lobo, Markus Rechsteiner, Birgit M Helmchen, et al.
Leukemia & Lymphoma|May 26, 2020
Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosisRudolf Benz, Kathrin Zimmermann, Markus Rechsteiner, et al.
BMC Clinical Pathology|June 3, 2016
Liver cancer with concomitant TP53 and CTNNB1 mutations: a case reportJuliane Friemel, Markus Rechsteiner, Marion Bawohl, et al.
Nature Communications|May 3, 2012
Reliable detection of subclonal single-nucleotide variants in tumour cell populationsMoritz Gerstung, Christian Beisel, Markus Rechsteiner, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Diagnostic Pathology|February 13, 2019
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern SwitzerlandAlexandra Grosse, Claudia Grosse, Markus Rechsteiner, et al.
Plos One|August 7, 2019
Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcomeClaudia Grosse, Alex Soltermann, Markus Rechsteiner, et al.
Histopathology|September 24, 2023
Pleomorphic adenoma with PLAG1 fusion as an isolated kidney mass: lessons learned from a challenging caseJoão Lobo, Markus Rechsteiner, Niels J Rupp, et al.
Frontiers in Medicine|May 16, 2022
Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney TransplantsOnur Sazpinar, Ariana Gaspert, Daniel Sidler, et al.
American Journal of Clinical Pathology|May 9, 2019
Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E MutationAnne-Laure Leblond, Markus Rechsteiner, Amy Jones, et al.
Oncotarget|January 5, 2017
VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinomaCaroline Fanja Razafinjatovo, Daniel Stiehl, Eva Deininger, et al.
Histopathology|April 11, 2022
Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative studyJoão Lobo, Markus Rechsteiner, Birgit M Helmchen, et al.
Leukemia & Lymphoma|May 26, 2020
Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosisRudolf Benz, Kathrin Zimmermann, Markus Rechsteiner, et al.
BMC Clinical Pathology|June 3, 2016
Liver cancer with concomitant TP53 and CTNNB1 mutations: a case reportJuliane Friemel, Markus Rechsteiner, Marion Bawohl, et al.
Nature Communications|May 3, 2012
Reliable detection of subclonal single-nucleotide variants in tumour cell populationsMoritz Gerstung, Christian Beisel, Markus Rechsteiner, et al.
Pageof 5